CLINICAL TRIALS PROFILE FOR RABAVERT

All Clinical Trials for RABAVERT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02374814 ↗	Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis	Completed	Walter Reed Army Institute of Research (WRAIR)	Phase 4	2015-03-24	The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
NCT02374814 ↗	Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis	Completed	State University of New York - Upstate Medical University	Phase 4	2015-03-24	The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	Kansas State University	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	Walter Reed Army Institute of Research (WRAIR)	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	State University of New York - Upstate Medical University	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT03264157 ↗	Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects	Completed	Bio Products Laboratory	Phase 2/Phase 3	2017-12-08	A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.

Clinical Trial Conditions for RABAVERT

Condition Name

Condition Name for RABAVERT
Intervention	Trials
Rabies	2
Healthy	1
Virus Diseases	1

Condition MeSH

Condition MeSH for RABAVERT
Intervention	Trials
Rabies	4
Virus Diseases	1

Clinical Trial Locations for RABAVERT

Trials by Country

Trials by Country for RABAVERT
Location	Trials
United States	8

Trials by US State

Trials by US State for RABAVERT
Location	Trials
New York	3
Maryland	1
Kansas	1
Florida	1
North Carolina	1

Clinical Trial Progress for RABAVERT

Clinical Trial Phase

Clinical Trial Phase for RABAVERT
Clinical Trial Phase	Trials
Phase 4	2
Phase 2/Phase 3	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for RABAVERT
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	1

Clinical Trial Sponsors for RABAVERT

Sponsor Name

Sponsor Name for RABAVERT
Sponsor	Trials
Walter Reed Army Institute of Research (WRAIR)	2
State University of New York - Upstate Medical University	2
Kansas State University	1

Sponsor Type

Sponsor Type for RABAVERT
Sponsor	Trials
Other	4
U.S. Fed	2
Industry	1